MA38885B1 - Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) - Google Patents
Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)Info
- Publication number
- MA38885B1 MA38885B1 MA38885A MA38885A MA38885B1 MA 38885 B1 MA38885 B1 MA 38885B1 MA 38885 A MA38885 A MA 38885A MA 38885 A MA38885 A MA 38885A MA 38885 B1 MA38885 B1 MA 38885B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- atom
- lower alkyl
- halogen
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La présente invention porte sur des composés de formule i dans laquelle y représente n ou c-r1' ; g représente un noyau aromatique ou hétéroaromatique à 5 ou 6 chaînons contenant 0, 1, 2 ou 3 hétéroatomes, choisi dans le groupe constitué par les noyaux phényle, pyridinyle à différentes positions de n, imidazolyle, pyrazinyle, pyrimidinyle, thiophényle, thiazolyle, pyrazolyle ou thiadiazolyle, qui sont éventuellement substitués par 1, 2 ou 3 substituants, choisis dans le groupe constitué par les substituants halogéno, alkyle inférieur, alcoxy inférieur, alcoxy inférieur substitué par halogène ou nrr' ; r et r' sont chacun indépendamment de l'autre l'atome d'hydrogène ou un groupe alkyle inférieur ou ils peuvent former conjointement avec l'atome n auquel ils sont attachés un groupe hétérocyclique saturé à cinq ou six chaînons qui peut contenir un atome d'oxygène ou groupe nh ou n-(alkyle inférieur) supplémentaire ; r1 représente l'atome d'hydrogène, un atome d'halogène ou un groupe alkyle inférieur substitué par halogène ; r1' représente l'atome d'hydrogène, un atome d'halogène ou un groupe alkyle inférieur substitué par halogène ; r2 représente l'atome d'hydrogène ou un groupe alkyle inférieur, alcoxyalkyle inférieur, cycloalkyle ou hétérocycloalkyle ; ou r2 peut former conjointement avec l'atome de carbone le plus proche dans un groupe g un groupe (ia), a représentant -ch2-, -ch2ch2 ou -c(ch3)2- ; r3 est un groupe phényle ou pyridinyle, l'atome n dans le groupe pyridinyle pouvant être en différentes positions ; ou sur un sel ou sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, sur un mélange racémique de ceux-ci ou sur son énantiomère et/ou isomère optique et/ou stéréoisomère correspondant. Il a été trouvé de manière inattendue que les composés de formule générale i sont des modulateurs allostériques positifs (pam) du récepteur métabotropique du glutamate 4 (mglu4), utiles pour le traitement de la maladie de parkinson, de l'anxiété, de vomissements, d'un trouble obsessionnel-compulsif, de l'autisme, pour la neuroprotection et pour le traitement d'un cancer, d'une dépression et du diabète de type 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13185856 | 2013-09-25 | ||
| PCT/EP2014/070100 WO2015044075A1 (fr) | 2013-09-25 | 2014-09-22 | Dérivés d'éthynyle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38885A1 MA38885A1 (fr) | 2017-12-29 |
| MA38885B1 true MA38885B1 (fr) | 2018-11-30 |
Family
ID=49230629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38885A MA38885B1 (fr) | 2013-09-25 | 2014-09-22 | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20160207890A1 (fr) |
| EP (1) | EP3049409B1 (fr) |
| JP (1) | JP6134441B2 (fr) |
| KR (1) | KR101757603B1 (fr) |
| CN (1) | CN105579447B (fr) |
| AR (1) | AR097721A1 (fr) |
| AU (1) | AU2014327504B2 (fr) |
| BR (1) | BR112016005994A2 (fr) |
| CA (1) | CA2924376A1 (fr) |
| CL (1) | CL2016000677A1 (fr) |
| CR (1) | CR20160075A (fr) |
| DK (1) | DK3049409T3 (fr) |
| EA (1) | EA029352B1 (fr) |
| ES (1) | ES2630319T3 (fr) |
| HK (1) | HK1220200A1 (fr) |
| HU (1) | HUE034849T2 (fr) |
| IL (1) | IL244039B (fr) |
| MA (1) | MA38885B1 (fr) |
| MX (1) | MX370341B (fr) |
| MY (1) | MY183953A (fr) |
| PE (1) | PE20160666A1 (fr) |
| PH (1) | PH12016500427A1 (fr) |
| PL (1) | PL3049409T3 (fr) |
| SG (1) | SG11201602029VA (fr) |
| SI (1) | SI3049409T1 (fr) |
| TW (1) | TWI527801B (fr) |
| UA (1) | UA116277C2 (fr) |
| WO (1) | WO2015044075A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015222303B2 (en) * | 2014-02-25 | 2019-02-28 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| WO2016146600A1 (fr) * | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Dérivés 3-(4-éthynylphényl)hexahydropyrimidine-2,4-dione en tant que modulateurs de mglur4 |
| CN107580598B (zh) * | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
| AR105556A1 (es) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
| WO2017031116A1 (fr) * | 2015-08-18 | 2017-02-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibiteurs de ku70/80 à petites molécules et utilisations associées |
| PE20190382A1 (es) | 2016-07-18 | 2019-03-08 | Hoffmann La Roche | Derivados etinilo |
| BR112021001131A2 (pt) | 2018-07-26 | 2021-04-20 | Domain Therapeutics | derivados de quinazolinona substituídos e seu uso como moduladores alostéricos positivos de mglur4 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10330359A (ja) * | 1997-03-31 | 1998-12-15 | Nippon Bayeragrochem Kk | フエニルアセチレン誘導体及び除草剤 |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| WO2008151184A1 (fr) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Dérivés benzamides modulateurs allostériques positifs récepteurs métabotropiques du glutamate 5 (mglur5) et leurs procédés de fabrication et d'utilisation |
| WO2011029104A1 (fr) * | 2009-09-04 | 2011-03-10 | Vanderbilt University | Potentialisateurs allostériques mglur4, composition et méthodes de traitement de dysfonctionnements neurologiques |
| RU2012139491A (ru) * | 2010-02-11 | 2014-03-20 | Вандербилт Юниверсити | Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| MX2012013031A (es) * | 2010-05-12 | 2012-12-17 | Univ Vanderbilt | Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica. |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| CN102503888A (zh) * | 2011-10-08 | 2012-06-20 | 西安交通大学 | 2-芳基-1,3-异喹啉二酮类抗肿瘤化合物及其合成方法和用途 |
-
2014
- 2014-09-22 DK DK14781474.3T patent/DK3049409T3/en active
- 2014-09-22 CN CN201480052343.0A patent/CN105579447B/zh active Active
- 2014-09-22 PE PE2016000237A patent/PE20160666A1/es active IP Right Grant
- 2014-09-22 JP JP2016517337A patent/JP6134441B2/ja active Active
- 2014-09-22 SI SI201430272T patent/SI3049409T1/sl unknown
- 2014-09-22 SG SG11201602029VA patent/SG11201602029VA/en unknown
- 2014-09-22 MY MYPI2016000532A patent/MY183953A/en unknown
- 2014-09-22 ES ES14781474.3T patent/ES2630319T3/es active Active
- 2014-09-22 BR BR112016005994A patent/BR112016005994A2/pt not_active Application Discontinuation
- 2014-09-22 KR KR1020167007447A patent/KR101757603B1/ko active IP Right Grant
- 2014-09-22 MA MA38885A patent/MA38885B1/fr unknown
- 2014-09-22 HU HUE14781474A patent/HUE034849T2/en unknown
- 2014-09-22 UA UAA201604513A patent/UA116277C2/uk unknown
- 2014-09-22 CA CA2924376A patent/CA2924376A1/fr not_active Abandoned
- 2014-09-22 PL PL14781474T patent/PL3049409T3/pl unknown
- 2014-09-22 AU AU2014327504A patent/AU2014327504B2/en not_active Ceased
- 2014-09-22 EP EP14781474.3A patent/EP3049409B1/fr active Active
- 2014-09-22 WO PCT/EP2014/070100 patent/WO2015044075A1/fr active Application Filing
- 2014-09-22 MX MX2016002717A patent/MX370341B/es active IP Right Grant
- 2014-09-22 AR ARP140103499A patent/AR097721A1/es unknown
- 2014-09-22 EA EA201690408A patent/EA029352B1/ru not_active IP Right Cessation
- 2014-09-23 TW TW103132854A patent/TWI527801B/zh not_active IP Right Cessation
-
2016
- 2016-02-09 IL IL244039A patent/IL244039B/en not_active IP Right Cessation
- 2016-02-16 CR CR20160075A patent/CR20160075A/es unknown
- 2016-03-04 PH PH12016500427A patent/PH12016500427A1/en unknown
- 2016-03-23 CL CL2016000677A patent/CL2016000677A1/es unknown
- 2016-03-25 US US15/081,573 patent/US20160207890A1/en not_active Abandoned
- 2016-07-15 HK HK16108345.7A patent/HK1220200A1/zh unknown
- 2016-09-30 US US15/283,010 patent/US9676732B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38885A1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
| MA42442A (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| KR950701323A (ko) | 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) | |
| MA35192B1 (fr) | Derives de pyrazole | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| PH12016501100B1 (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
| MA35113B1 (fr) | 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5 | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| MA33802B1 (fr) | Dérivés d'éthynyle | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| MY165141A (en) | Pyrazolidin-3-one derivatives | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| MA29343B1 (fr) | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine | |
| IN2014CN02477A (fr) | ||
| RU2011137408A (ru) | Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии | |
| RU2404180C1 (ru) | Замещенные 8-сульфонил-2,3,4,5-тетрагидро-1н-гамма-карболины, лиганды, фармацевтическая композиция, способ их получения и применения | |
| MA34251B1 (fr) | Derives amido-tropane | |
| RS53498B1 (en) | SYNTHESIS OF THE SUBSTITUTED PIRAZOLINE CARBOXAMIDINE DERIVATIVES |